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Identity 
Other names: HSP75, HSP90L 
HGNC (Hugo): TRAP1 
Location: 16p13.3 
Local order: Genes flanking TRAP1 (from telomere to 
centromere): 
- NLRC3: 16p13.3, NLR family, CARD domain 
containing 3; 
- BTBD12: 16p13.3, BTB (POZ) domain containing 
12;  
- DNASEI: 16p13.3, Deoxyribonuclease I; 
- TRAP-1;  
- CREBBP: 16p13.3, CREB binding protein; 
- ADCY9: 16p13.3, adenylate cyclase 9;  
- SRL: 16p13.3, sarcalumenin. 
Note: TRAP-1 gene encodes for an intra-mitochondrial 
protein highly homolog to members of the Hsp90 
family which play a fundamental role in protein 
folding, protein degradation and signal transduction. 
TRAP1 is highly conserved through evolution, binds 
ATP and exhibits an ATPase activity that is inhibited 
by both geldanamycin and radicicol. 
DNA/RNA 
Description 
According to the NCBI map viewer, TRAP1 gene maps 
to NC_000016.9 and encompasses about 60 Kb. The 
gene contains 18 exons. 
Transcription 
The mRNA is 2263 bp long. 
Pseudogene 
No TRAP1 pseudogenes were reported in human. 
 
Map of the chromosome 16p13.3 region showing the in scale 
position of the TRAP1 gene and its organization in exons 
(purple boxes) and introns (blue lines). 
Protein 
Description 
TRAP1 has a molecular weight of 80110 Da and 
consists of 704 amino acid residues. 
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Schematic representation of the domain organization of TRAP1 protein (Data from SwissProt, InterPro, Ensembl). 
 
It contains a N-terminal domain (transit peptide) 
required for its transport from cytoplasm to 
mitochondria, a middle domain involved in ATPase 
activity, a charged domain, and a C-terminal domain. 
Of note, it lacks the charged domain found immediately 
after the N-terminal domain in other HSP90 proteins. It 
contains four ATP binding sites in 119, 158, 171 and 
205 position. TRAP1 undergoes to following post 
translational modifications: 
- N6-acetyllysine in 87, 332, 382, 424, 466 position;  
- phosphotyrosine in 366 position; 
- phosphoserine in 401 position; 
- phosphothreonine in 494 position. 
Expression 
Northern blot analysis has revealed that the protein is 
expressed, although at different levels, in skeletal 
muscle, liver, heart, brain, kidney, pancreas, lung a d 
placenta. 
Localisation 
TRAP1 is located in mitochondria, although 
immunoelectron microscopy has been provided 
evidence that it can also be found at specific 
extramitochondrial sites (pancreatic zymogen granules, 
insulin secretory granules, cardiac sarcomeres, nuclei 
of pancreatic and heart cells and cell surface of bl od 
vessel endothelial cells). 
Function 
TRAP1 binds the intracellular N-terminal half of the 
tumor necrosis factor receptor (TNFR1) and, thus, it is
involved in signal transduction pathways TNFR-1-
mediated. Through these pathways TRAP1 up-
regulates the expression of different genes, such as 
those involved in cell cycle, cell motility and metas atic 
spread. In particular, in the brain the interaction 
TRAP1-TNFR1 is involved in modulating the 
expression of the N-cadherin, that is downregulated in 
TRAP1 knockdown cells, and in regulating the inter-
cellular adhesion and synaptic morphology of neuronal 
cells. TRAP1 interacts, by means of a LxCxE motif, 
also with the T antigen-binding domain of the 
retinoblastoma protein (Rb), during the mitosis and 
after heat shock promoting in vitro the refolding of RB, 
and with the tumor suppressor EXT1 and EXT2, and 
the mitochondrial ribosomal protein S12 3'-UTR. In 
contrast with Hsp90 protein, TRAP1 does not associate 
with the classic Hsp90 co-chaperones p23 and Hop  
(p60). Recently, it has been demonstrated that TRAP1 
is an in vitro substrate of PARPs (Poly(ADP-ribose) 
polymerases). PARPs catalyze the transfer of adenine 
phosphate ribose units from NAD to proteins and are 
involved in DNA repair, transcription, mitosis and 
telomere length maintenance. 
TRAP1 plays an important role in protecting cells 
against oxidative stress and apoptosis. To this purpose 
it has been observed that TRAP1 suppression in 
mitochondria induces the apoptosis process by means 
of ROS production. What is more TRAP1 
overexpression decreases ROS production and 
preserves mitochondrial membrane potential during the 
ischemia-like condition of glucose deprivation and 
preserves ATP levels and cell viability during oxygen-
glucose deprivation. TRAP1 protects cells from 
granzyme M-mediated apoptosis by preventing the 
accumulation of ROS. The cleavage of TRAP1 by the 
granzyme abolishes its antagonistic function to ROS, 
and leads to ROS accumulation. It has been proposed 
that mitochondrial homeostasis is differentially 
regulated in tumor versus normal cells, in part dueto 
elevated expression of TRAP1 in mitochondria. The 
overexpression of TRAP1 might buffer mitochondrial 
proteins from direct damage caused by exposure to 
prolonged oxidative stress. To this regard, it was 
reported that TRAP1 is a member of a prosurvival 
mitochondrial pathway highly activated in tumor cells 
that antagonizes the proapototic activity of cyclophilin 
D (CypD), a protein involved in the regulation of the 
mitochondrial permeability transition pore.  
TRAP1-overexpression induces a decrease in levels of 
ROS, Caveolin-1, glutathione peroxidase (GPX), and 
manganese superoxide dismutase (MnSOD) as well as 
of the senescence-associated beta-galactosidase in cells 
treated with deferoxamine (DFO), an iron chelator 
responsible of mitochondrial dysfunction and 
senescence-like cellular morphology. It has been shown 
that TRAP1 is a MYC target, thus it may be considere  
involved in increased apoptosis in MYC-
overexpressing cells and accountable for the elevated 
susceptibility of such cells to tumor necrosis factor 
alpha-mediated apoptosis. 
Hypoxia conditions induce an up-regulation of protein 
levels of TRAP1 in osteoarthritic chondrocyte and i 
cartilage tissue, and in cardiomyocytes, in which 
TRAP1 plays a protective role by regulating the 
opening of the mitochondrial permeability transition 
pore. 
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TRAP1 is phosphorylated by PINK1, a serine/threonine 
protein kinase that localizes to mitochondria, and this
phosphorylation mediates the PINK1 protective effects 
against oxidative stress-induced cell death by 
preventing the release of cytochrome c from 
mitochondria. PINK1 mutations that cause the 
Parkinson disease induce a reduced phosporylation of 
TRAP1 and thus a sensitization of the cells to the lethal 
effects of reactive oxygen species. 
The expression of TRAP1 in heat stress conditions is 
modulated by the common variability of the 
mitochondrial DNA. In fact TRAP1 is over-expressed 
at both mRNA and intra-mitochondrial protein levels in 
cybrid line harbouring mtDNA of haplogroup H than in 
the other cybrid lines (lines J, U, X, T). 
Homology 
- Canis familiaris: TRAP1 (TNF receptor-associated 
protein 1) 
- Pan troglodytes: TRAP1 (TNF receptor-associated 
protein 1) 
- Bos taurus: TRAP1 (TNF receptor-associated protein 
1) 
- Rattus norvegicus: Trap1 (TNF receptor-associated 
protein 1) 




Six SNPs in the TRAP1 gene are found associated with 
neurological diseases. In particular: 
- schizophrenia: SNP rs2108430, T/C, intron 3; 
- bipolar disorders: SNP rs6500552, T/C, intron 1; 
- major depression: SNP rs1639150, T/C, intron 1; SNP 
rs2108430, T/C, intron 3; SNP rs13926, C/G, exon 9 




It has been shown that TRAP1 is overexpressed at both 
mRNA and protein level in human primary and 
metastatic prostate cancer tissues but not expressed in 
normal prostate or benign prostatic hyperplasia. This 
up-regulation is also shown in different cell lines such 
as PC-3, LNCaP, 293, K562 and HeLa. Silencing of 
TRAP1 gene by siRNAs in prostate cancer cells 
induces apoptotic cell death thus giving evidence upon 
an antiapoptotic function of TRAP1. In presence of 
gamitrinibs, a Hsp90 inhibithor acting as ATPase 
antagonists that accumulates in the mitochondria of 
human tumor cell lines causing rapid tumor cell death, 
it is observed a complete death of prostate cancer cells
but not of nontransformed BPH-1 cells. On the other  
 
 
hand, the introduction in these cells of TRAP1 induces  
the gamitrinibs-mediated cell death. By protein 
microarray analysis of serum from patients affected by 
prostate cancer, obtained before and after treatment 
with GM-CSF secreting whole cell immunotherapy 
(GVAX® immunotherapy), it was demonstrated an 
antibody response to TRAP1 in post-treatment samples. 
In particular, analysis of antibody induction in 
metastatic, castration-resistant prostate cancer 
(mCRPC) patients, individuated only from 2 of 3 phase 
1/2 studies of prostate cancer immunotherapy (G-9803 
and G-0010), revealed an induction of TRAP1 antibody 
and its association with survival time. 
Ovarian cancer 
Note 
Several studies have identified TRAP1 as a potential 
target in ovarian cancer. In fact TRAP1 is upregulated 
in human cisplatin (CCDP)-resistant ovarian tumor 
cells, in endometrial cancer following progesterone 
stimulation and in estrogen receptor-positive ovarian 
cell lines. Moreover the TRAP1 estrogen-induced up-
regulation is reversed by the anti-estrogen tamoxifen. 
For ovarian cancer patients treated with the aromatase 
inhibitor letrozole, differences in expression levels of 
TRAP1, such as in aromatase expression, were 
observed between tumors from responsive/stable 
patients and tumors from patients whose disease was 
progressing, using serum levels of CA125 marker as an 
indicator of response. 
Colorectal carcinoma 
Note 
TRAP1 expression is up-regulated in colorectal 
carcinoma. In fact TRAP1 levels were increased in HT-
29 colorectal carcinoma cells in which, as in other 
neoplastic cells, the above overexpression is involved 
in 5-fluorouracil-, oxaliplatin- and irinotecan-resistant 
phenotypes. Conversely, the inhibition of TRAP1 
activity by shepherdin, a TRAP1 ATPase antagonist, 
has been shown to rescue the resistance to apoptosis 
induced by oxaliplatin and irinotecan in colorectal 
carcinoma cells resistant to the single agents. These 
results suggest that TRAP1 could be a component of a 




Microarray analysis carried out by using total RNA 
from 32 pathologically-confirmed cases of poorly-
differentiated nasopharyngeal carcinoma (NPC) and 
RNA from 24 normal non-cancerous nasopharyngeal 
tissues (NP) have demonstrated that TRAP1 is up-
regulated in NPC compared to NP, thus indentifying 
this protein as potential candidate biomarker in 
nasopharyngeal carcinoma. 
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Lymphoma 
Note 
In ALK-positive anaplastic large-cell lymphoma, a type 
of non-Hodgkin lymphoma, the knockdown of TRAP1 
determine cell death induced by TRAIL or doxorubicin. 
Expression levels of TRAP1 has been shown increased 
in EBV infected B cells and, since this infection 
resulted in the induction of ROS in Burkitt's 
lymphoma, it was suggested that over-expression of 
TRAP1 play a role in the protection of the EBV 
infected cells against ROS and apoptosis. 
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